LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone in systolic heart failure (HF) regimens over the past 25 years. Their ability to block the renin-angiotensin-aldosterone system and their vasodilatory properties has repeatedly been shown to lower morbidity and mortality in patients with HF having reduced ejection fractions. In August 2014, the New England Journal of Medicine published a large trial studying a novel LCZ696 (angiotensin-neprilysin inhibition) agent against enalapril, an ACEI. In the phase III trial, LCZ696 demonstrated superiority to enalapril in composite death from cardiovascular causes and hospitalization for HF. The trial was stopped early due to overwhelming benefit of the study agent. This article provides an extensive review of the mechanism of action, pharmacokinetic properties, clinical efficacy, safety, and tolerability of LCZ696.

• Authors: Antony Q Pham, Yesha Patel, Brittany Gallagher
• Journal: Journal of pharmacy practice (J Pharm Pract) Vol. 28 Issue 2 Pg. 137-45 (Apr 2015) ISSN: 1531-1937 [Electronic] United States
• PMID: 25864789 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2015.

Chemical References

• Aminobutyrates
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Biphenyl Compounds
• Drug Combinations
• Tetrazoles
• Valsartan
• sacubitril and valsartan sodium hydrate drug combination

Topics

• Aminobutyrates (pharmacokinetics, pharmacology, therapeutic use)
• Angiotensin Receptor Antagonists (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Animals
• Biphenyl Compounds
• Drug Combinations
• Heart Failure (drug therapy)
• Humans
• Rats
• Tetrazoles (pharmacokinetics, pharmacology, therapeutic use)
• Valsartan